Australien - engelska - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - nitrazepam, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - insomnia, organic and inorganic in origin.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; calcium hydrogen phosphate dihydrate; brilliant scarlet 4r - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; quinoline yellow; calcium hydrogen phosphate dihydrate; green s - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; calcium hydrogen phosphate dihydrate - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Singapore - engelska - HSA (Health Sciences Authority)

gilead sciences singapore pte. ltd. - tenofovir disoproxil 245mg eqv tenofovir disoproxil fumarate - tablet, film coated - 300mg/ tablet - tenofovir disoproxil 245mg eqv tenofovir disoproxil fumarate 300 mg

Australien - engelska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 41.583 mg - tablet, film coated - excipient ingredients: macrogol 6000; mannitol; purified talc; colloidal anhydrous silica; sodium stearylfumarate; microcrystalline cellulose; silicon dioxide; lactose; hypromellose; maize starch - noumed rosuvastatin is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: noumed rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). noumed rosuvastatin is indicated to: - reduce the risk of nonfatal myocardial infarction - reduce the risk of nonfatal stroke - reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia: noumed rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding familial hypercholesterolaemia). prior to initiating therapy with noumed rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 20.791 mg - tablet, film coated - excipient ingredients: macrogol 6000; hypromellose; silicon dioxide; microcrystalline cellulose; sodium stearylfumarate; lactose; colloidal anhydrous silica; purified talc; maize starch; mannitol - noumed rosuvastatin is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: noumed rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). noumed rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia noumed rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding familial hypercholesterolaemia). prior to initiating therapy with noumed rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 10.396 mg - tablet, film coated - excipient ingredients: lactose; colloidal anhydrous silica; maize starch; hypromellose; sodium stearylfumarate; microcrystalline cellulose; silicon dioxide; purified talc; mannitol; macrogol 6000 - noumed rosuvastatin is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: noumed rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). noumed rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia noumed rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding familial hypercholesterolaemia). prior to initiating therapy with noumed rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 5.198 mg - tablet, film coated - excipient ingredients: hypromellose; maize starch; sodium stearylfumarate; colloidal anhydrous silica; silicon dioxide; mannitol; lactose; microcrystalline cellulose; purified talc; macrogol 6000 - noumed rosuvastatin is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: noumed rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). noumed rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia noumed rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding familial hypercholesterolaemia). prior to initiating therapy with noumed rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - topiramate, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.